Production (Stage)
Cognition Therapeutics, Inc.
CGTX
$0.322
$0.02377.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.14% | 21.08% | -41.13% | 23.06% | -12.41% |
| Total Depreciation and Amortization | -36.62% | 1.43% | 4.48% | 15.52% | -12.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.74% | -40.40% | -21.88% | -16.03% | 27.54% |
| Change in Net Operating Assets | -77.12% | -154.01% | 1,347.06% | -135.20% | -68.80% |
| Cash from Operations | -17.84% | -22.35% | -14.24% | 17.21% | -32.77% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 39.49% | -5.41% | -2.21% | -1.69% | 0.56% |
| Issuance of Common Stock | -88.69% | 2,410.70% | 690.77% | -99.47% | 368.95% |
| Repurchase of Common Stock | -- | -- | 100.00% | 79.25% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -88.61% | 3,359.27% | 338.41% | -101.15% | 391.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -386.22% | 145.97% | -6.26% | -229.25% | 255.86% |